Open the mobile version, with barcode scanning
Class I Ongoing

Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20.

Why: Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.

Company
Fresenius Kabi USA, LLC
Lake Zurich, IL, United States
Reported
Sep 2, 2026
Recall started
Aug 10, 2026
Where sold
Nationwide in the USA
Amount
4,643 20mL-vials
Full product description
Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20.
Lots / codes affected
Lot: 16UI07, Exp 08/31/2028

Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.